Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Leap Therapeutics Inc (LPTX)

Leap Therapeutics Inc (LPTX)
0.2800 x 2 0.2975 x 56
Post-market by (Cboe BZX)
0.2922 +0.0266 (+10.02%) 04/07/25 [NASDAQ]
0.2800 x 2 0.2975 x 56
Post-market 0.2975 +0.0053 (+1.81%) 19:51 ET
Quote Overview for Mon, Apr 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.2507
Day High
0.3049
Open 0.2507
Previous Close 0.2656 0.2656
Volume 465,500 465,500
Avg Vol 6,016,575 6,016,575
Stochastic %K 11.92% 11.92%
Weighted Alpha -80.68 -80.68
5-Day Change -0.0129 (-4.23%) -0.0129 (-4.23%)
52-Week Range 0.2223 - 4.7900 0.2223 - 4.7900
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,958
  • Shares Outstanding, K 41,258
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,560 K
  • EBIT $ -70 M
  • EBITDA $ -70 M
  • 60-Month Beta 0.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.34
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.84
  • Most Recent Earnings $-0.37 on 03/26/25
  • Next Earnings Date 05/12/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 382.05% ( -73.71%)
  • Historical Volatility 122.15%
  • IV Percentile 88%
  • IV Rank 49.43%
  • IV High 756.04% on 02/18/25
  • IV Low 16.56% on 06/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 15
  • Volume Avg (30-Day) 136
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 4,593
  • Open Int (30-Day) 4,671

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.38
  • Number of Estimates 1
  • High Estimate -0.38
  • Low Estimate -0.38
  • Prior Year -0.51
  • Growth Rate Est. (year over year) +25.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2223 +31.44%
on 04/04/25
Period Open: 0.4392
0.6500 -55.05%
on 03/26/25
-0.1470 (-33.47%)
since 03/07/25
3-Month
0.2223 +31.44%
on 04/04/25
Period Open: 3.4800
3.5000 -91.65%
on 01/08/25
-3.1878 (-91.60%)
since 01/07/25
52-Week
0.2223 +31.44%
on 04/04/25
Period Open: 2.5400
4.7900 -93.90%
on 10/30/24
-2.2478 (-88.50%)
since 04/05/24

Most Recent Stories

More News
Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

KURA : 5.76 (-2.21%)
SHPH : 0.4425 (+13.46%)
LPTX : 0.2922 (+10.02%)
NXTC : 0.3858 (-1.10%)
ACET : 0.6201 (-2.91%)
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline

While sirexatamab combined with tislelizumab and chemotherapy showed some activity in biomarker-specific populations, the study failed to generate a clear positive signal on progression-free survival endpoints....

PINK : 27.26 (-0.58%)
IWC : 100.24 (-0.48%)
VXF : 154.14 (-0.78%)
LPTX : 0.2922 (+10.02%)
Leap Therapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX : 0.2922 (+10.02%)
Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.2922 (+10.02%)
Leap Therapeutics Announces Reverse Stock Split

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.2922 (+10.02%)
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX : 0.2922 (+10.02%)
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today...

LPTX : 0.2922 (+10.02%)
Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.2922 (+10.02%)
Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported...

LPTX : 0.2922 (+10.02%)
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01

/PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced...

LPTX : 0.2922 (+10.02%)

Business Summary

Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 0.3687
2nd Resistance Point 0.3368
1st Resistance Point 0.3145
Last Price 0.2922
1st Support Level 0.2603
2nd Support Level 0.2284
3rd Support Level 0.2061

See More

52-Week High 4.7900
Fibonacci 61.8% 3.0451
Fibonacci 50% 2.5062
Fibonacci 38.2% 1.9672
Last Price 0.2922
52-Week Low 0.2223

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades